Ernsting Mark J, Hoang Bryan, Lohse Ines, Undzys Elijus, Cao Pinjiang, Do Trevor, Gill Bethany, Pintilie Melania, Hedley David, Li Shyh-Dar
Drug Discovery Program, Ontario Institute for Cancer Research, 101 College Street, Suite 800, Toronto, Ontario M5G 0A3, Canada; Faculty of Engineering and Architectural Science, Ryerson University, Toronto, Ontario M5B 1Z2, Canada.
Drug Discovery Program, Ontario Institute for Cancer Research, 101 College Street, Suite 800, Toronto, Ontario M5G 0A3, Canada.
J Control Release. 2015 May 28;206:122-30. doi: 10.1016/j.jconrel.2015.03.023. Epub 2015 Mar 21.
Pancreatic ductal adenocarcinomas are characterized by the desmoplastic reaction, a dense fibrous stroma that has been shown to be supportive of tumor cell growth, invasion, and metastasis, and has been associated with resistance to chemotherapy and reduced patient survival. Here, we investigated targeted depletion of stroma for pancreatic cancer therapy via taxane nanoparticles. Cellax-DTX polymer is a conjugate of docetaxel (DTX), polyethylene glycol (PEG), and acetylated carboxymethylcellulose, a construct which condenses into well-defined 120nm particles in an aqueous solution, and is suitable for intravenous injection. We examined Cellax-DTX treatment effects in highly stromal primary patient-derived pancreatic cancer xenografts and in a metastatic PAN02 mouse model of pancreatic cancer, focusing on specific cellular interactions in the stroma, pancreatic tumor growth and metastasis. Greater than 90% of Cellax-DTX particles accumulate in smooth muscle actin (SMA) positive cancer-associated fibroblasts which results in long-term depletion of this stromal cell population, an effect not observed with Nab-paclitaxel (Nab-PTX). The reduction in stromal density leads to a >10-fold increase in tumor perfusion, reduced tumor weight and a reduction in metastasis. Consentingly, Cellax-DTX treatment increased survival when compared to treatment with gemcitabine or Nab-PTX in a metastatic PAN02 mouse model. Cellax-DTX nanoparticles interact with the tumor-associated stroma, selectively interacting with and depleting SMA positive cells and macrophage, effects of which are associated with significant changes in tumor progression and metastasis.
胰腺导管腺癌的特征是促结缔组织增生反应,即一种致密的纤维性基质,已被证明可支持肿瘤细胞的生长、侵袭和转移,并与化疗耐药性及患者生存率降低有关。在此,我们研究了通过紫杉烷纳米颗粒靶向清除基质用于胰腺癌治疗的情况。Cellax-DTX聚合物是多西他赛(DTX)、聚乙二醇(PEG)和乙酰化羧甲基纤维素的共轭物,该构建体在水溶液中可凝聚成明确的120nm颗粒,适合静脉注射。我们研究了Cellax-DTX在高度富含基质的原发性患者来源的胰腺癌异种移植模型以及胰腺癌转移PAN02小鼠模型中的治疗效果,重点关注基质中的特定细胞相互作用、胰腺肿瘤的生长和转移。超过90%的Cellax-DTX颗粒积聚在平滑肌肌动蛋白(SMA)阳性的癌症相关成纤维细胞中,这导致该基质细胞群体长期减少,而纳米白蛋白结合型紫杉醇(Nab-PTX)未观察到这种效果。基质密度的降低导致肿瘤灌注增加10倍以上,肿瘤重量减轻,转移减少。同样,在转移性PAN02小鼠模型中,与吉西他滨或Nab-PTX治疗相比,Cellax-DTX治疗可提高生存率。Cellax-DTX纳米颗粒与肿瘤相关基质相互作用,选择性地与SMA阳性细胞和巨噬细胞相互作用并使其减少,其作用与肿瘤进展和转移的显著变化相关。